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Certain types of DNA lesions activate a cellular 
signaling network that is usually referred to as the DNA 
damage response (DDR). The phosphatidyl-indsitol(3)-
like kinases (PIKKs) ATM, ATR and DNA-PKcs are 
critical regulators of the mammalian DDR. ATM and 
DNA-PKcs are mainly activated in response to DNA 
double-strand breaks (DSBs) while the related kinase 
ATR is activated by a broader spectrum of DNA lesions 
including stalled DNA replication forks and DNA repair 
intermediates that contain long stretches of single-stranded 
DNA (ssDNA). Once activated, PIKKs phosphorylate a 
large number of downstream targets that are involved in 
the regulation of repair processes, the activation of cell 
cycle checkpoints and the triggering of apoptosis, should 
the damage be too severe to repair. Among the targets 
phosphorylated and activated by PIKKs are the two 
checkpoint kinases Chk1 and Chk2 that serve as signal 
transducer molecules. While Chk2 is downstream of the 
ATM signaling cascade, Chk1 is mainly activated through 
phosphorylation by ATR (reviewed in [1]). 
The atypical Ser/Thr protein kinase target of 
rapamycin (TOR) also belongs to the PIKK family of 
kinases, but it has until recently not been implicated 
in the DDR. It mainly regulates nutrient-dependent 
signaling pathways underlying cell growth, proliferation 
and survival. TOR-dependent signaling pathways are 
often deregulated in cancer. TOR exists in two different 
complexes: TORC1 and TORC2. TORC1 primarily 
regulates growth and is involved in modulation of protein 
synthesis, ribosome biogenesis and autophagy. The cellular 
functions of TORC2 are less well understood, mainly 
because there is so far no specific inhibitor available for 
TORC2. In contrast to the starvation-like phenotypes 
observed upon disruption or inhibition of TORC1, loss of 
TORC2 generates diverse effects that often show species 
or cell type specificity (reviewed in [2]).
Recently, experiments carried out in yeast suggested 
a specific role of TORC2 in the maintenance of genome 
stability in response to the induction of DSBs and in 
response to oxidative or replicative stress [3,4]. Results by 
Selvarajah et al. [5] suggest that TORC2 is also implicated 
in the cellular response to DNA damage in mammalian 
cells. Specifically, it appears that TORC2 is required for 
the optimal phosphorylation and activation of Chk1 in 
response to treatment of cancer cell lines with Etoposide, 
a cytotoxic anticancer drug that causes DSBs. Failure to 
fully activate Chk1 in response to DNA damage usually 
results in defective cell cycle checkpoint activation and 
as a consequence, increased cell death. This is exactly 
what the authors observed: simultaneous treatment of 
several cancer cell lines with the TOR inhibitor PP242 and 
Etoposide led to abrogated cell cycle arrest and decreased 
survival when compared to treatment with Etoposide 
alone. While PP242 inhibits both TORC1 and TORC2, 
only depletion of the TORC2-specific scaffold protein 
Rictor had an effect on Chk1 phosphorylation, while 
depletion of the TORC1-specific subunit Raptor had no 
effect, thus indicating that the observed DDR phenotypes 
are specific for TORC2-dependent signaling events.
This raises the question as to how TORC2 regulates 
Chk1 phosphorylation in response to DNA-damaging 
chemotherapeutics. Surprisingly, at least in some cell 
lines, TORC2 inhibition not only led to a reduced Chk1 
phosphorylation in response to Etoposide, but also to 
reduced Chk1 protein levels, probably as a result of 
reduced Chk1 translation. The reduced Chk1 expression 
appears to be specific to Etoposide treatment since 
ultraviolet light that also strongly activates the ATR-Chk1 
route of the DDR did not decrease Chk1 protein levels 
upon TOR inhibition, even though Chk1 phosphorylation 
was still compromised.
Chk1 is a direct ATR target an in principle it is 
possible that the reduced Chk1 phosphorylation observed 
upon TORC2 inhibition is caused by a reduced ATR 
activation.  Since efficient ATR activation depends on the 
generation ssDNA at sites of DNA lesion or blocked DNA 
replication forks, it will be worth exploring if ssDNA 
generation at sites of Etoposide-induced DNA damage 
requires TORC2 activity. In this context it is interesting 
to note that TORC2 inactivation was recently shown to 
increase the toxic effects of drugs that interfere with DNA 
replication in a mouse model for T-cell leukemia [6]. 
Is there any translational significance of these 
findings? Provided that TORC2 inhibition has few 
effects on its own, it may be worth exploring if TORC2 
inhibition could sensitize tumor cells to chemotherapeutic 
drugs that cause DNA damage and/or interfere with 
DNA replication. Of course this would first require the 
successful development of a TORC2-specific inhibitor.
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